Andreas Lennartsson
Acute myeloid leukemia (AML) has a poor prognosis in both adults and children, with a long-term survival of only 25% and 60% respectively. No major development has occurred of the treatment since, the last decades and the majority of treatments for AML consist of cytotoxic drugs with low specificity.
PDFShare this article
Journal of Genetics and DNA Research received 3 citations as per Google Scholar report
